Technology Offerings

New Insights Into Alzheimer’s Diagnosis and Treatment

A-beta-autoantibodies were isolated from the serum of Alzheimer patients. The cDNA and amino acid sequences of the variable regions of the heavy and the light chains were determined and all possible pairings of the chains were expressed in mammalian cells.<br>

A number of these pairings were found to bind with higher affinity to A-beta dimers than to A-beta monomers. One of these was shown to possess biological activities potentially useful for the treatment of Alzheimer´s disease.<br> Consensus sequences were determined and used to prepare human anti-beta-amyloid antibodies useful for preventing or treating neurodementing diseases like Alzheimer´s. These human anti-beta-amyloid antibodies are suitable for detecting and measuring the progression of neurodementing disease and methods are provided for delaying the onset or progression of these diseases.

Further Information: PDF

TransMIT Gesellschaft für Technologietransfer mbH
Phone: +49 (0)641/943 64-12

Contact
Dr. Peter Stumpf

Comments (0)

Write a comment